161 related articles for article (PubMed ID: 33479584)
1. Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial.
Kadowaki T; Wang G; Rosenstock J; Yabe D; Peng Y; Kanasaki K; Mu Y; Mattheus M; Keller A; Okamura T; Johansen OE; Marx N
Diabetol Int; 2021 Jan; 12(1):87-100. PubMed ID: 33479584
[TBL] [Abstract][Full Text] [Related]
2. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Marx N; Kolkailah AA; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto RD; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK
JAMA Cardiol; 2024 Feb; 9(2):134-143. PubMed ID: 38170502
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
Espeland MA; Pratley RE; Rosenstock J; Kadowaki T; Seino Y; Zinman B; Marx N; McGuire DK; Andersen KR; Mattheus M; Keller A; Weber M; Johansen OE
Diabetes Obes Metab; 2021 Feb; 23(2):569-580. PubMed ID: 33185002
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA
Inagaki N; Yang W; Watada H; Ji L; Schnaidt S; Pfarr E; Okamura T; Johansen OE; George JT; von Eynatten M; Rosenstock J; Perkovic V; Wanner C; Cooper ME; Alexander JH; Komuro I; Nangaku M
Diabetol Int; 2020 Apr; 11(2):129-141. PubMed ID: 32206483
[TBL] [Abstract][Full Text] [Related]
5. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
Rosenstock J; Kahn SE; Johansen OE; Zinman B; Espeland MA; Woerle HJ; Pfarr E; Keller A; Mattheus M; Baanstra D; Meinicke T; George JT; von Eynatten M; McGuire DK; Marx N;
JAMA; 2019 Sep; 322(12):1155-1166. PubMed ID: 31536101
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
Guthrie R
Postgrad Med; 2020 May; 132(4):314-319. PubMed ID: 32164494
[TBL] [Abstract][Full Text] [Related]
7. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
[TBL] [Abstract][Full Text] [Related]
8. Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
Rosenstock J; Kolkailah AA; McGuire DK; Espeland MA; Mattheus M; Pfarr E; Lund SS; Marx N;
Diabetes Obes Metab; 2023 Jun; 25(6):1453-1463. PubMed ID: 36700416
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial.
Cooper ME; Rosenstock J; Kadowaki T; Seino Y; Wanner C; Schnaidt S; Clark D; Johansen OE;
Diabetes Obes Metab; 2020 Jul; 22(7):1062-1073. PubMed ID: 32037653
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA.
Ghosh S; Mukhopadhyay P; Pandey P; Chatterjee P; Pandit K
Diab Vasc Dis Res; 2020; 17(6):1479164120973653. PubMed ID: 33213193
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
Rosenstock J; Marx N; Neubacher D; Seck T; Patel S; Woerle HJ; Johansen OE
Cardiovasc Diabetol; 2015 May; 14():57. PubMed ID: 25990013
[TBL] [Abstract][Full Text] [Related]
12. Comparison of gliclazide
Mohan V; Wangnoo S; Das S; Dhediya R; Gaurav K
World J Diabetes; 2022 Dec; 13(12):1168-1183. PubMed ID: 36578872
[TBL] [Abstract][Full Text] [Related]
13. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; von Eynatten M; George JT; Johansen OE; Wanner C;
Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
Biessels GJ; Janssen J; van den Berg E; Zinman B; Espeland MA; Mattheus M; Johansen OE;
BMC Neurol; 2018 Jan; 18(1):7. PubMed ID: 29334906
[TBL] [Abstract][Full Text] [Related]
15. Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.
Patorno E; Schneeweiss S; Gopalakrishnan C; Martin D; Franklin JM
Diabetes Care; 2019 Dec; 42(12):2204-2210. PubMed ID: 31239281
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus.
Chilton R
Expert Rev Endocrinol Metab; 2013 Jul; 8(4):345-349. PubMed ID: 30736150
[TBL] [Abstract][Full Text] [Related]
17. Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.
Biessels GJ; Verhagen C; Janssen J; van den Berg E; Wallenstein G; Zinman B; Espeland MA; Johansen OE
Diabetologia; 2021 Jun; 64(6):1235-1245. PubMed ID: 33559704
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
19. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
Li YR; Tsai SS; Chen DY; Chen ST; Sun JH; Chang HY; Liou MJ; Chen TH
Cardiovasc Diabetol; 2018 Jan; 17(1):2. PubMed ID: 29301579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
